Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology has submitted its marketing authorization application for the approval of PB272 (neratinib) as extended adjuvant treatment of HER2-positive early stage breast cancer in Europe.

Puma Biotechnology, Inc.